Seizure risk in brain tumor patients with conversion to generic levetiracetam
- 21 November 2009
- journal article
- case report
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 98 (1) , 137-141
Abstract
Breakthrough seizure activity has been reported with conversion from brand name to generic anticonvulsants. This has prompted several organizations to support physician notification of generic substitution and patient consent. Recently, a generic formulation of levetiracetam has become available. Risk of seizures with generic levetiracetam has yet to be reported. Literature was reviewed regarding risk of generic substitution. Four cases of seizure activity in primary brain tumor patients after conversion from Keppra to generic levetiracetam are reported. In all cases, there was no evidence of tumor growth or concurrent illness that would increase the risk of seizures. In three cases, the patients have remained seizure free with conversion back to Keppra. The final patient required an increased dose of levetiracetam. As has been described with generic substitution of other anticonvulsants, patients switched to generic levetiracetam may be at risk for breakthrough seizure activity.Keywords
This publication has 16 references indexed in Scilit:
- Effects of Antiepileptic Drug Substitutions on Epileptic Events Requiring Acute CarePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2009
- Bioequivalence of antiepileptic drugs: How close is close enough?Current Neurology and Neuroscience Reports, 2009
- The use of generic medication in epilepsy: A review of potential issues and challengesEuropean Journal of Paediatric Neurology, 2009
- Drug interactions between chemotherapeutic regimens and antiepilepticsClinical Therapeutics, 2008
- Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsyNeurology, 2007
- Compulsory Generic Switching of Antiepileptic Drugs: High Switchback Rates to Branded Compounds Compared with Other Drug ClassesEpilepsia, 2007
- LETTERS/COMMENTARYEpilepsia, 2007
- Lower phenytoin serum levels in persons switched from brand to generic phenytoinNeurology, 2004
- Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors [RETIRED]Neurology, 2000
- The Pathogenesis of Tumour Associated EpilepsyActa Neurochirurgica, 2000